logo
Share SHARE
FONT-SIZE Plus   Neg

BioLineRx Announces Extension Of Patent For BCM By USPTO - Quick Facts

BioLineRx (BLRX) said an Issue Notification has been received from the United States Patent and Trademark Office granting 1,787 days of Patent Term Adjustment for the patent claiming the composition of BCM (BL-1040), a novel medical device for prevention of cardiac remodeling following an acute myocardial infarction.

Accordingly, the term of this patent will now extend through at least the end of April 2029, which is almost three years longer than previously reported by the company. Additional patents claiming the BL-1040 composition and its use for the treatment of ventricular remodeling and congestive heart failure due to acute myocardial infarction are granted or pending in Europe, Japan, Canada, Korea, Mexico, Israel, India, China and Australia.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Shares of Hennes & Mauritz AB or H&M were plunging around 13 percent in Sweden after the retailer reported lower sales in its fourth quarter with weakness in H&M brand's physical stores. However, H&M brand's online sales and sales of the group's other brands continued to develop well, the company said. We urge investors to take advantage of the weakness in shares of Ichor Holdings, Ltd. (ICHR), because we believe the company's 2017 acquisitions bode well for the stock. ICHR is more than 30% off its recent 52-week, intra-day high, and this pullback in the absence of any sharp change in fundamentals, positions the stock for at least 20% potential upside from current levels. French aircraft maker Dassault Aviation SA said Wednesday that following repeated delays, it has terminated a contract with French defense company Safran for its Silvercrest engine that was intended to power Dassault's Falcon 5X business jet.
comments powered by Disqus
Follow RTT